Multiple sclerosis and pain

Neurological Research

Volumn 34, Issue 9, 2012, Pages 829-841

  Nick, Saeed Talebzadeh ^a   Robertsa, Charles ^b   Billiodeaux, Seth ^b   Davis, Debra Elliott ^a   Zamanifekri, Behrouz ^a   Sahraian, Mohammad Ali ^c   Alekseeva, Nadejda ^d   Munjampalli, Sai ^a   Roberts, Joann ^e   Minagar, Alireza ^a  

^a Louisiana State University Health Sciences Center at Shreveport   (United States)

^b LOUISIANA STATE UNIVERSITY   (United States)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d OVERTON BROOKS VA MEDICAL CENTER   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glossopharyngeal neuralgia; Migraine; Multiple sclerosis; Pain

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; BACLOFEN; BENZODIAZEPINE DERIVATIVE; CANNABIDIOL; CANNABINOID DERIVATIVE; CAPSAICIN; CARBAMAZEPINE; CLONAZEPAM; CORTICOTROPIN; ETIRACETAM; GABAPENTIN; GLATIRAMER; INTERFERON; LAMOTRIGINE; METHYSERGIDE; MISOPROSTOL; NATALIZUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; OXCARBAZEPINE; PIZOTIFEN; PREGABALIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TETRAHYDROCANNABINOL; TIAGABINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID;

ADL DISABILITY; ADRENOLEUKODYSTROPHY; ANALGESIA; ANTIPHOSPHOLIPID SYNDROME; ANXIETY DISORDER; BRAIN STEM; CADASIL; CEREBROVASCULAR ACCIDENT; CHRONIC PAIN; CLINICAL FEATURE; COMORBIDITY; COMPLEX REGIONAL PAIN SYNDROME TYPE I; COMPLEX REGIONAL PAIN SYNDROME TYPE II; CONSTIPATION; CYANOCOBALAMIN DEFICIENCY; DEMYELINATION; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DROWSINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DYSESTHESIA; EXTREMITY CENTRAL PAIN; FAMILY HISTORY; FLU LIKE SYNDROME; GENETIC DISORDER; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GLOSSOPHARYNGEAL NEURALGIA; HERPES ZOSTER; HUMAN; HUMAN T CELL LEUKEMIA VIRUS INFECTION; HYPOTENSION; IMAGE RECONSTRUCTION; INCIDENCE; INFLAMMATION; LHERMITTE SIGN; LYSOSOME STORAGE DISEASE; MENTAL DISEASE; MENTAL HEALTH; METABOLIC DISORDER; MIGRAINE; MIGRAINE WITH AURA; MULTIPLE SCLEROSIS; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL PAIN; MYELITIS; NEOPLASM; NERVE CELL LESION; NEURALGIA; NEUROIMMUNOLOGY; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PAIN ASSESSMENT; PAINFUL DYSESTHESIA; PAINFUL TONIC SPASM; PATHOPHYSIOLOGY; PONS; PREVALENCE; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SARCOIDOSIS; SJOEGREN SYNDROME; SMOKING; SOCIAL DISABILITY; SPASTICITY; SPINAL DEGENERATIVE DISEASE; SPINAL VASCULAR MALFORMATION; SPINE DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; TENSION HEADACHE; TRIGEMINUS NEURALGIA; URINE RETENTION; VASCULAR DISEASE; VISUAL IMPAIRMENT; WHITE MATTER LESION;

HUMANS; MULTIPLE SCLEROSIS; PAIN;

EID: 84867913597     PISSN: 01616412     EISSN: 17431328     Source Type: Journal    
DOI: 10.1179/1743132812Y.0000000082     Document Type: Review

References (165)

1. Dirckx JH. (Ed). Stedman's concise medical dictionary for the health professions. Baltimore, MD: Lippincott Williams and Wilkins; 2001.
2. Marchettini P, Formaglio E, Lacerenza M. Pain as a heralding symptom in multiple sclerosis. J Neurol Sci. 2006;27:S294-S296.
3. Archibald CJ, McGrath PJ, Ritvo PG, Fisk JD, Bhan V, Maxner CE, et al. Pain prevalence, severity and impact in a clinic sample of multiple sclerosis patients. Pain. 1994;58:89-93.
4. Moulin DE, Foley KM, Ebers GC. Pain syndromes in multiple sclerosis. Neurology. 1988;38:1830-1934.
5. Stenager E, Knudsen L, Jensen K. Acute and chronic pain syndromes in multiple sclerosis: a 5-year follow-up study. Ital J Neurol Sci. 1995;16:629-632.
6. Svendsen KB, Jensen TS, Overvad K, Hansen HJ, Koch-Henriksen N, Bach FW. Pain in patients with multiple sclerosis: a population-based study. Arch Neurol. 2003;60:1089-194.
7. Grasso MG, Clemenzi A, Tonini A, Pace L, Casillo P, Cuccaro A, et al. Pain in multiple sclerosis: a clinical and instrumental approach. Mult Scler. 2008;14:506-513.
8. Kalia LV, O'Connor PW. Severity of chronic pain and its relationship to quality of life in multiple sclerosis. Mult Scler. 2005;11:322-327.
9. O'Connor AB, Schwid SR, Herrmann DN, Markman JD, Dworkin RH. Pain associated with multiple sclerosis: systematic review and proposed classification. Pain. 2008;137:96-111.
10. Grau-López L, Sierra S, Martínez-Cáceres E, Ramo-Tello C. Analysis of the pain in multiple sclerosis patients. Neurología. 2011;26:208-213.
11. Clifford DB, Trotter JL. Pain in multiple sclerosis. Arch Neurol. 1984;41:1270-1272.
12. Sadovnick A, Eisen K, Ebers GC, Paty DW. Cause of death in patients attending multiple sclerosis clinics. Neurology. 1991;41:1193.
13. Rushton JG, Olafson RA. Trigeminal neuralgia associated with multiple sclerosis. A case report. Arch Neurol. 1965;13:383-386.
14. Jensen TS, Rasmussen P, Reske-Nielsen E. Association of trigeminal neuralgia with multiple sclerosis: clinical and pathological features. Acta Neurol Scand. 1982;65:182-189.
15. Ashkenazi A, Levin M. Three common neuralgias. How to manage trigeminal, occipital, and postherpetic pain. Postgrad Med. 2004;116:16-18, 21-4, 31-32.
16. Hartmann M, Rottach KG, Wohlgemuth WA, Pfadenhauer K. Trigeminal neuralgia triggered by auditory stimuli in multiple sclerosis. Arch Neurol. 1999;56:731-733.
17. Hooge JP, Redekop WK. Trigeminal neuralgia in multiple sclerosis. Neurology. 1995;45:1294-1296.
18. Gass A, Kitchen N, MacManus DG, Moseley IF, Hennerici MG, Miller DH. Trigeminal neuralgia in patients with multiple sclerosis: lesion localization with magnetic resonance imaging. Neurology. 1997;49:1142-1144.
19. Love S, Gradidge T, Coakham HB. Trigeminal neuralgia due to multiple sclerosis: ultrastructural findings in trigeminal rhizotomy specimens. Neuropathol Appl Neurobiol. 2001;27:238-244.
20. Cruccu G, Biasiotta A, Di Rezze S, Fiorelli M, Galeotti F, Innocenti P, et al. Trigeminal neuralgia and pain related to multiple sclerosis. Pain. 2009;143:186-191.
21. Hilton DA, Love S, Gradidge T, Coakham HB. Pathological findings associated with trigeminal neuralgia caused by vascular compression. Neurosurgery. 1994;35:299-303.
22. Jannetta PJ. Arterial compression of the trigeminal nerve at the pons in patients with trigeminal neuralgia 1967. J Neurosurg. 2007;107:216-219.
23. Deshmukh VR, Hott JS, Tabrizi P, Nakaji P, Feiz-Erfan I, Spetzler RF. Cavernous malformation of the trigeminal nerve manifesting with trigeminal neuralgia: case report. Neurosurgery. 2005;56:E623.
24. Burchiel KJ. Editorial: glossopharyngeal neuralgia. J Neurosurg. 2011;115:934-935.
25. Meaney JF, Eldridge PR, Dunn LT, Nixon TE, Whitehouse GH, Miles JB. Demonstration of neurovascular compression in trigeminal neuralgia with magnetic resonance imaging. Comparison with surgical findings in 52 consecutive operative cases. J Neurosurg. 1995;83:799-805.
26. Cruccua G, Gronsethb J, Alksne J, Argoff C, Brainin M, Burchiel K, et al. AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol. 2008;15:1013-1028.
27. Pöllmann W, Feneberg W. Current management of pain associated with multiple sclerosis. CNS Drugs. 2008;22:291-324.
28. Ratis G, Sicuro L, Giordano M, Pomatto E. Glossopharyngeal neuralgia. Minerva Stomatol. 1990;39:755-758.
29. Minagar A, Sheremata WA. Glossopharyngeal neuralgia and MS. Neurology. 2000;54:1368-1370.
30. Cemil AI. Treatment of a patient with glossopharyngeal neuralgia by the anterior tonsillar pillar method. Case Rep Neurol. 2011;3:27-31.
31. Kawashima M, Matsushima T, Inoue T, Mineta T, Masuoka J, Hirakawa N. Microvascular decompression for glossopharyngealneuralgia through the transcondylar fossa (supracondylar transjugular tubercle) approach. Neurosurgery. 2010;66(6 Suppl Operative):275-280.
32. Al-Araji AH, Oger J. Reappraisal of Lhermitte's sign in multiple sclerosis. Mult Scler. 2005;11:398-402.
33. Solaro C, Messmer Uccelli M. Management of pain in multiple sclerosis: a pharmacological approach. Nat Rev Neurol. 2011;7:519-527.
34. Osterberg A, Boivie J. Central pain in multiple sclerosis -sensory abnormalities. Eur J Pain. 2010;14:104-110.
35. Solaro C, Messmer Uccelli M. Pharmacological management of pain in patients with multiple sclerosis. Drugs. 2010;70:1245-254.
36. Burey AR, Abla-Yao S. Successful treatment of central pain in a multiple sclerosis patient with epidural stimulation of the dorsal root entry zone. Pain Med. 2010;11:127-132.
37. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuro pathic pain treatment: an evidence based proposal. Pain. 2005;118:289-305.
38. Solaro C, Tanganelli P, Messmer Uccelli M. Pharmacological treatment of pain in multiple sclerosis. Expert Rev Neurother. 2007;7:1165-1174.
39. Solaro C, Brichetto G, Amato MP, Cocco E, Colombo B, D'Aleo G, et al. The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. Neurology. 2004;63:919-921.
40. Fryze W, Zaborski J, Członkowska A. Pain in the course of multiple sclerosis. Neurol Neurochir Pol. 2002;36:275-284.
41. Spissu A. Anatomic correlates of painful tonic spasms in multiple sclerosis. Mov Disord. 1999;14:331-335.
42. Killestein J, Polman C. The therapeutic value of cannabinoids in MS: real or imaginary? Mult Scler. 2004;10:339-340.
43. Hemmer B, Hartung HP. Toward the development of rational therapies in multiple sclerosis: what is on the horizon? Ann Neurol. 2007;62:314-326.
44. Habek M, Karni A, Balash Y, Gurevich T. The place of the botulinum toxin in the management of multiple sclerosis. Clin Neurol Neurosurg. 2010;112:592-596.
45. Schwartzman RJ, Gurusinghe C, Gracely E. Prevalence of complex regional pain syndrome in a cohort of multiple sclerosis patients. Pain Physician. 2008;11:133-136.
46. Das A, Puvanendran K. Syringomyelia and complex regional pain syndrome as complications of multiple sclerosis. Arch Neurol. 1999;56:1021-1024.
47. Gellman H, Keenan MA, Stone L, Hardy SE, Waters RL, Stewart C. Reflex sympathetic dystrophy in brain-injured patients. Pain. 1992;51:307-311.
48. Rowbotham MC. Pharmacologic management of complex regional pain syndrome. Clin J Pain. 2006;22:425-429.
49. Bruehl S, Chung OY. Psychological and behavioral aspects of complex regional pain syndrome management. Clin J Pain. 2006;22:430-437.
50. Poser CM, Presthus J, Horsda O. Clinical characteristics of autopsy-proven multiple sclerosis. Neurology. 1966;16:791-798.
51. Watkins MS, Espir M. Migraine and multiple sclerosis. J Neurol Neurosurg Psychiatry. 1969;32:35-37.
52. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 2nd edition. Cephalalgia. 2004;24:1-159.
53. Gee JR, Chang J, Dublin AB, Vijayan N. The association of brainstem lesions with migraine-like headache: an imaging study of multiple sclerosis. Headache. 2005;45:670-677.
54. D'Amico D, La Mantia L, Rigamonti A, Usai S, Mascoli N, Milanese C, et al. Prevalence of primary headaches in people with multiple sclerosis. Cephalalgia. 2004;24:980-984.
55. Vacca G, Marano E, Brescia Morra V, Lanzillo R, De Vito M, Parente E, et al. Multiple sclerosis and headache co-morbidity. A case-control study. Neurol Sci. 2007;28:133-135.
56. Kister I, Caminero AB, Herbert J, Lipton RB. Tension-type headache and migraine in multiple sclerosis. Curr Pain Headache Rep. 2010;14:441-448.
57. Putzki N, Katsarava Z. Headache in multiple sclerosis. Curr Pain Headache Rep. 2010;14:316-320.
58. Yetimalar Y, Sicil Y, Inceoglu AK, Eren S, Başoǧlu M. Unusual primary manifestations of multiple sclerosis. N Z Med J. 2008;121:47-59.
59. Mariotti P, Viviana N, Cianfoni A, Stefanini C, De Rose P, Martinelli D, et al. Migraine-like headache and status migrainosus as attacks of multiple sclerosis in a child. Pediatrics. 2010;126:e459-e464.
60. Freedman MS, Gray TA. Vascular headache: a presenting symptoms of multiple sclerosis. Can J Neurol Sci. 1989;16:63-66.
61. Martinez Sobrepera HJ, Cabrera Gomez JA, Tuero Iglesias A. Exogenous factors in the aetiology of multiple sclerosis in Cuba. A study of cases and controls. Rev Neurol. 2001;33:931-937.
62. Zorzon M, Zivadinov R, Nasuelli D, Dolfini P, Bosco A, Bratina A, et al. Risk factors of multiple sclerosis: a case-control study. Neurol Sci. 2003;24:242-247.
63. Katsiari CG, Vikelis M, Paraskefopoulou ES, Sfikakis PP, Mitsikostas DD. Headache in systemic lupus erythematosus vs multiple sclerosis: a prospective comparative study. Headache. 2011;51:1398-1407.
64. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50:121-127.
65. Rolak LA, Fleming JO. The differential diagnosis of multiple sclerosis. Neurologist. 2007;13:57-72.
66. Jacobi C, Stingele K, Kretz R, Hartmann M, Storch-Hagenlocher B, Breitbart A, et al. Neuromyelitis optica (Devic's syndrome) as first manifestation of systemic lupus erythematosis. Lupus. 2006;15:107-1.
67. Ordonez L, Skromne E, Ontaneda D, Rivera VM. Multiphasic disseminated encephalomyelitis, systemic lupus erythematosus and antiphospholipid syndrome. Clin Neurol Neurosurg. 2007;109:102-105.
68. Chapman J, Rand JH, Brey RL, Levine SR, Blatt I, Khamashta MA, et al. Non-stroke neurological syndromes associated with antiphospholipid antibodies. Lupus. 2003;12:514-517.
69. Hughes GRV. Migraine, memory loss, and 'multiple sclerosis'. Neurologic features of the antiphospholipid (Hughes') syndrome. Postgrad Med J. 2003;79:81-83.
70. Kitigawa Y. Neurological aspects in antiphospholipid syndrome. Rinsho Shinkeigaku. 2003;43:744-747.
71. La Mantia L, Erbetta A. Headache and inflammatory disorders of the central nervous system. Neurol Sci. 2004;25(Suppl 3):S148-S153.
72. Charlier C, Nunes H, Trinchet JC, Roullet E, Mouthon L, Beaugrand M, et al. Evolution of previous sarcoidosis under type 1 interferons given for severe associated disease. Eur Respir J. 2005;25:570-573.
73. Ferreira S, D'Cruz DP, Hughes GR. Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand? Rheumatology. 2005;44:434-42.
74. Marangoni S, Argentiero V, Tavolato B. Neurosarcoidosis: clinical description of 7 cases with a proposal for a new diagnostic strategy. J Neurol. 2006;253:488-495.
75. Trojano M, Paolicelli D. The differential diagnosis of multiple sclerosis: classification and clinical features of relapsing and progressive neurological syndromes. Neurol Sci. 2001;22(Suppl 2):S98-S102.
76. Carmosino MJ, Brousseau KM, Arciniegas DB, Corboy JR. Initial evaluations for multiple sclerosis in a university multiple sclerosis center. Arch Neurol. 2005;62:585-590.
77. Silberstein SD, Lipton RB, Goadsby PJ. Headache in clinical practice. 2nd ed. London: Martin Dunitz Ltd; 2002. p. 76.
78. Kirchmann M. Migraine with aura: new understanding from clinical epidemiologic studies. Curr Opin Neurol. 2006;19:286-293.
79. Eggers SD. Migraine-related vertigo: diagnosis and treatment. Curr Neurol Neurosci Rep. 2006;6:106-215.
80. Thomsen LL, Olesen J. Sporadic hemiplegic migraine. Cephalagia. 2004;24:1016-1023.
81. Eriksen M, Thomsen LL, Olesen J. Implications of clinical subtypes of migraine with aura. Headache. 2006;46:286-297.
82. Freedom T, Jay WM. Migraine with and without headache. Semin Ophthalmol. 2003;18:210-217.
83. Al-Twaijri WA, Shevell MI. Pediatric migraine equivalents: occurrence and clinical features in practice. Pediatr Neurol. 2002;26:365-368.
84. Di Rosa G, Spanó M, Pustorino G, Ferrari MD, Stam AH, Sgró DL, et al. Alternating hemiplegia of childhood successfully treated with topiramate: 18 months of follow-up. Neurology. 2006;66:146.
85. Shevell MI. Acephalgic migraine of childhood. Pediatr Neurol. 1996;14:211-215.
86. Evans RW, Rolak LA. Migraine versus multiple sclerosis. Headache. 2001;41:97-98.
87. Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology. 2009;72:117-124.
88. Kister I, Caminero AB, Monteith TS, Soliman A, Bacon TE, Bacon JH, et al. Migraine is comorbid with multiple sclerosis and associated with a more symptomatic MS course. J Headache Pain. 2010;11:417-425.
89. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann Neurol. 2005;58:840-846.
90. Minagar A, Gonzalez-Toledo E, Pinkston J, Jaffe SL. Neuroimaging in multiple sclerosis. Int Rev Neurobiol.2005;67:165-201.
91. Callen DJA, Shroff MM, Branson HM, Lotze T, Li DK, Stephens D, et al. MRI in the diagnosis of pediatric multiple sclerosis. Neurology. 2009;72:961-967.
92. Jacome DE, Leborgne J. MRI studies in basilar artery migraine. Headache. 1990;30:88-90.
93. Cooney BS, Grossman RI, Farber RE, Goin JE, Galetta SL. Frequency of magnetic resonance imaging abnormalities in patients with migraine. Headache. 1996;36:616-621.
94. Kruit MC, van Buchem MA, Hofman PA, Bakkers JT, Terwindt GM, Ferrari MD, et al. Migraine as a risk factor for subclinical brain lesions. JAMA. 2004;291:427-434.
95. Kruit MC, Launer LJ, Ferrari MD, van Buchem MA. Infarcts in the posterior circulation territory in migraine. The population-based MRI CAMERA study. Brain. 2005;128: 2068-2077.
96. Kruit MC, Launer LJ, Ferrari MD, van Buchem MA. Brain stem and cerebellar hyperintense lesions in migraine. Stroke.2006;37:1109-1112.
97. Bekieslićska-Figatowska M. T2-hyperintense foci on brain MR imaging. Med Sci Monit. 2004;10(Suppl 3):80-87.
98. Haas DC, Kent PF, Friedman DI. Headache caused by a single lesion of multiple sclerosis in the peri-aqueductal gray area. Headache. 1993;33:452-455.
99. Tortorella P, Rocca MA, Colombo B, Annovazzi P, Comi G, Filippi M. Assessment of MRI abnormalities of the brainstem from patients with migraine and multiple sclerosis. J Neurol Sci. 2006;244:137-141.
100. Welch KM, Nagesh V, Aurora SK, Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache. 2010;41:629-637.
101. Rovaris, M, Bozzali M, Rocca MA, Colombo B, Filippi M. An MR study of tissue damage in the cervical cord of patients with migraine. J Neurol Sci. 2001;183:43-46.
102. Pöllmann W, Erasmus LP, Feneberg W, Then Bergh F, Straube A. Interferon beta but not glatiramer acetate therapy aggravates headaches in MS. Neurology. 2002;59:636-639.
103. Gold R, Rieckmann P, Chang P, Abdalla J; PRISMS Study Group. The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study. Eur J Neurol. 2005;12:649-656.
104. Koch-Henriksen N, Sørensen PS, Christensen T, Frederiksen J, Ravnborg M, Jensen K, et al. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology. 2006;66:1056-1060.
105. Banwell B, Reder AT, Krupp L, Tenembaum S, Eraksoy M, Alexey B, et al. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology. 2006;66:472-476.
106. Neilley LK, Goodin DS, Goodkin DE, Hauser SL. Side effect profile of interferon beta-1b in MS: results of an open label trial. Neurology. 1996;46:552-554.
107. Pöllmann W, Erasmus LP, Feneberg W, Straube A. The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS. Neurology. 2006;66:275-277.
108. Nortvedt MW, Riise T, Myhr KM, Nyland HI, Hanestad BR. Type I interferons and the quality of life of multiple sclerosis patients. Results from a clinical trial on interferon alfa-2a. Mult Scler. 1999;5:317-322.
109. Galetta SL, Markowitz C. US FDA-approved diseasemodifying treatments for multiple sclerosis. Review of adverse effect profiles. CNS Drugs. 2005;19:239-252.
110. Reess J, Haas J, Gabriel K, Fuhlrott A, Fiola M. Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-1a (AvonexH) therapy. Mult Scler. 2002;8:15-18.
111. Río J, Nos C, Bonaventura I, Arroyo R, Genis D, Sureda B, et al. Corticosteroids, ibuprofen, and acetaminophen for IFNb-1a flu symptoms in MS. Neurology. 2004;63:525-528.
112. Leuschen MP, Filipi M, Healey K. A randomized open label study of pain medications (naproxen, acetaminophen and ibuprofen) for controlling side effects during initiation of IFN bb-1a therapy and during its ongoing use for relapsingremitting multiple sclerosis. Mult Scler. 2004;10:636-642.
113. Khromov A, Segal M, Nissinoff J, Fast A. Migraines linked to interferon-b treatment of multiple sclerosis. Am J Phys Med Rehabil. 2005;84:644-647.
114. Ghezzi A. Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian co-operative study. Neurol Sci. 2005;26(Suppl 4):S183-S186.
115. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebocontrolled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899-910.
116. Comi G, O'Connor P, Montalban X, Antel J, Radue EW, Karlsson G, et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler. 2010;16:197-207.
117. Ferrari MD. Migraine. Lancet. 1998;351:1043-51.
118. Buzzi MG, Moskowitz MA. The pathophysiolog of migraine: year 2005. J Headache Pain. 2005;6:105-111.
119. Bowsher D. The management of central post-stroke pain. Postgrad Med J. 1995;71:598-604.
120. Bowsher D. Central pain: clinical and physiological characteristics. J Neurol Neursurg Psychiatry. 1996;61:62-69.
121. Österberg A, Boivie J, Thuomas KA. Central pain in multiple sclerosis - prevalence and clinical characteristics. Eur J Pain. 2004;9:531-542.
122. Smith KJ, McDonald WI. The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease. Phil Trans R Soc Lond B. 1999;354:1649-1673.
123. Poser CM. The multiple sclerosis trait and the development of multiple sclerosis: genetic vulnerability and environmental effect. Clin Neurol Neurosurg. 2006;108:227-233.
124. Thacker EL, Mirzaei F, Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol. 2006;59:499-503.
125. Cook SD. Does Epstein-Barr virus cause multiple sclerosis? Rev Neurol Dis. 2004;1:115-123.
126. Alvarez-Lafuente R, García-Montojo M, De las Heras V, Bartolomé M, Arroyo R. Clinical parameters and HHV-6 active replication in relapsing-remitting multiple sclerosis patients. J Clin Virol. 2006;37(Suppl 1):S24-S26.
127. Perez-Cesari C, Saniger MM, Sotelo J. Frequent association of multiple sclerosis with varicella and zoster. Acta Neurol Scand. 2005;112:417-419.
128. Leavell R, Ray CG, Ferry PC, Minnich LL. Unusual acute neurologic presentations with Epstein-Barr virus infection. Arch Neurol. 1986;43:186-188.
129. Mack KJ. What incites new daily persistent headache in children? Pediatr Neurol. 2004;31:122-125.
130. Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology. 2005;129:819-826.
131. Crawford SG, Kaplan BJ, Kinsbourne M. Are families of children with reading difficulties at risk for immune disorders and nonrighthandedness? Cortex. 1994;30:281-292.
132. Lauer K. Divergent risk of multiple sclerosis in two Anabaptist communities in America. Med Hypoth. 2006;67:969-974.
133. Kantarci O, Wingerchuk D. Epidemiology and natural history of multiple sclerosis: new insights. Curr Opin Neurol. 2006;19:248-54.
134. Mark BL, Carson JA. Vitamin D and autoimmune disease -implications for practice from the multiple sclerosis literature. J Am Diet Assoc. 2006;106:418-424.
135. Lips P. Vitamin D physiology. Prog Biophys Mol Biol. 2006;92:4-8.
136. Thys-Jacobs, S. Vitamin D and calcium in menstrual migraine. Headache. 1994;34:544-546.
137. Thys-Jacobs S. Alleviation of migraines with therapeutic vitamin D and calcium. Headache. 1994;34:590-592.
138. Breslau N, Lipton RB, Stewart WF, Schultz LR, Welch KM. Comorbidity of migraine and depression: investigating potential etiology and prognosis. Neurology. 2003;60:1308-1312.
139. Paparrigopoulos T, Ferentinos P, Kouzoupis A, Koutsis G, Papadimitriou GN. The neuropsychiatry of multiple sclerosis: focus on disorders of mood, affect and behaviour. Int Rev Psychiatry. 2010;22:14-21.
140. Sandyk R, Awerbuch GI. The co-occurrence of multiple sclerosis and migraine headache: the serotoninergic link. Int J Neurosci. 1994;76:249-257.
141. Zeinstra EM, Wilczak N, Wilschut JC, Glazenburg L, Chesik D, Kroese FG, et al. 5HT(4) agonists inhibit interferongamma- induced MHC class II and B7 costimulatory molecules expression on cultured astrocytes. J Neuroimmunol. 2006;179:191-195.
142. Musgrave T, Benson C, Wong G, Browne I, Tenorio G, Rauw G, et al. The MAO inhibitor phenelzine improves functional outcomes in mice with experimental autoimmune encephalomyelitis (EAE). Brain Behav Immun. 2011;25:1677-1688.
143. Taler M, Gil-Ad I, Korob I, Weizman A. The immunomodulatory effect of the antidepressant sertraline in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Neuroimmunomodulation. 2011;18:117-122.
144. Moja PL, Cusi C, Sterzi RR, Canepari C. Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. Cochrane Database Syst Rev. 2005;3:CD002919.
145. Russell MB, Olesen J. Increased familial risk and evidence of genetic factor in migraine. BMJ. 1995;311:541-544.
146. Stewart WF, Bigal ME, Kolodner K, Dowson A, Liberman JN, Lipton RB. Familial risk of migraine: variation by proband age at onset and headache severity. Neurology. 2006;66:344-348.
147. Tepper SJ, Rapoport A, Sheftell F. The pathophysiology of migraine. Neurologist. 2001;7:279-286.
148. Alviggi C, Carrieri PB, Pivonello R, Scarano V, Pezzella M, De Placido G, et al. Association of pelvic endometriosis with alopecia universalis, autoimmune thyroiditis and multiple sclerosis. J Endocrinol Invest. 2006;29:182-189.
149. Prat E, Tomaru U, Sabater L, Park DM, Granger R, Kruse N, et al. HLA-DRB5*0101 and -DRB1*1501 expression in the multiple sclerosis-associated HLA-DR15 haplotype. J Neuroimmunol. 2005;167:108-119.
150. Rainero I, Fasano E, Rubino E, Rivoiro C, Valfre W, Gallone S, et al. Association between migraine and HLA-DRB1 gene polymorphisms. J Headache Pain. 2005;6:185-7.
151. Rainero I, Dall'Omo AM, Rubino E, Valfre W, Fasano ME, Rivoiro C, et al. HLA-DRB1 genotyping in Italian migraine patients. Neurosci Lett. 2006;393:90-93.
152. Walther EU, Hohlfeld R. Multiple sclerosis. Side effects of interferon beta therapy and their management. Neurology. 1999;53:1622-1627.
153. Longoni M, Ferrarese C. Inflammation and excitotoxicity: role in migraine pathogenesis. Neurol Sci. 2006;27(Suppl 2):S107-S110.
154. Buzzi MG, Moskowitz MA, Shimizu T, Heath HH. Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacol. 1991;30:1193-1200.
155. Moskowitz MA, Cutrer FM. Sumatriptan: a receptor-targeted treatment for migraine. Ann Rev Med. 1993;44:145-154.
156. Sarchielli P, Alberti A, Baldi A, Coppola F, Rossi C, Pierguidi L, et al. Proinflammatory cytokines, adhesion molecules, and lymphocyte integrin expression in the internal jugular blood of migraine patients without aura assessed ictally. Headache. 2006;46:200-207.
157. Fidan I, Yüksel S, Ymir T, Irkeç C, Nur Aksakal F. The importance of cytokines, chemokines and nitric oxide in pathophysiology of migraine. J Neuroimmunol. 2006;171:184-188.
158. Empl M, Sostak P, Riedel M, Schwarz M, Müller N, Fö rderreuther S, et al. Decreased sTNF-RI in migraine patients? Cephalalgia. 2003;23:55-8.
159. Moreno B, Jukes, JP, Vergara-Irigaray N, Errea O, Villoslada P, Perry VH, et al. Systemic inflammation induces axon injury during brain inflammation. Ann Neurol. 2011;70:932-42.
160. Benarroch EE. Nitric oxide, a pleiotropic signal in the nervous system. Neurology. 2011;77:1568-76.
161. Cambron M, D'Haeseller M, Laureys G, Clinckers R, Debruyne J, De Keyser J. White-matter astrocytes, axonal energy metabolism, and axonal degeneration in multiple sclerosis. J Cereb Blood Flow Metab. 2012;32:413-424.
162. Chrisopherson K, Hromas R. Chemokine regulation of normal and pathologic immune responses. Stem Cells. 2001;19:388-396.
163. Jeffery DR, Mandler RN, Davis LE. Transverse myelitis. Retrospective analysis of 33 cases, with differentiation of cases associated with multiple sclerosis and parainfectious events. Arch Neurol. 1993;50:532-535.
164. Cervera-Deval J, Morant-Guillen MP, Fenollosa-Vasquez P, Serra-Escorihuela M, Vilchez-Padilla J, Burguera J. Social handicaps of multiple sclerosis and their relation to neurological alterations. Arch Phys Med Rehabil. 1994;75:1223-1227.
165. Paisley S, Beard S, Hunn A, Wight J. Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: a systematic review. Mult Scler. 2002;8:319-329.